Align Technology is using a Swiss oral health study to cement its dominance in digital dentistry. But who is truly owning the data?
NYC Health + Hospitals celebrates a milestone in **robotic-assisted bronchoscopy**. But behind the PR spin lies a critical debate on medical technology adoption and cost.
Russian scientists unveil a breakthrough cancer treatment technology. But the real story isn't the science; it's the geopolitical chessboard.
The new map of biomedical translational science isn't about progress; it's about control. Discover who's truly winning in the science-to-market race.
The real shockwave from OpenAI targeting healthcare isn't better diagnoses; it's the massive centralization of patient and provider data.
Forget the PR fluff. Unpacking how new scientific tools unlock disease mechanisms reveals a dangerous centralization of power in biotech.
Align Technology's Q4 2025 earnings call on Feb 4th isn't just about Invisalign revenue; it's a critical barometer for the entire **orthodontic technology** sector's future.
New echocardiogram and Cardiac MRI technology aren't just better pictures; they signal a seismic shift in diagnostic power, threatening traditional cardiology roles.
The retirement of a key surgical technology instructor isn't just local news; it's a symptom of a deeper crisis in workforce pipeline.
The FDA's Digital Health COE isn't just about innovation; it's a quiet power play shaping the future of digital health regulation.
AI is boosting neuroprotective drug trials for stroke, but who truly profits from this precision medicine revolution? The real battle is over data ownership.
A new ultra-sensitive imaging system promises earlier cancer detection, but the real story is the disruption it brings to multi-billion dollar diagnostic markets.